Intellectual Property
Leveraging a Novel Drug Discovery Platform
Cybin is engineering novel, next-generation molecules by selectively modifying tryptamine serotonin receptor agonist (TSRA) scaffolds, leading to the development of new, proprietary active pharmaceutical ingredients (APIs).
Cybin’s proprietary molecules have potential for improved safety, bioavailability, pharmacokinetic profiles and controlled delivery. We aim to fully unlock and optimize the therapeutic benefits of these molecules for patients and providers.
This approach has been integral to the discovery and development of our lead clinical-stage assets, CYB003, our proprietary deuterated psilocin program in development for the treatment of Major Depressive Disorder, and CYB004, our deuterated DMT program in development for the treatment of Generalized Anxiety Disorder.
Advancing Innovative Drug Delivery Systems
Cybin is leveraging efficient delivery systems to provide a direct path to the brain through bypassing first-pass liver metabolism. The goal of this approach is to deliver:
Fast onset of action
Improved dosing control
Short duration treatment
Low variability
Reduced side effects/ favorable, well-tolerated side effect profile
Less invasive / more convenient and patient-friendly dosing methods
Cybin’s proprietary delivery systems are broadly applicable across many compounds, including both deuterated and non-deuterated compounds targeting the 5-HT receptor.
Patents
Cybin has multiple patent filings covering a wide range of novel compounds from different psychedelic classes, including claims to targeted structural modifications to improve the drug pharmacokinetic characteristics and safety profiles without altering their receptor binding.
Cybin’s novel drug delivery platform claims are expected to enable administration of the psychedelic drugs with faster onset of effect, improved bioavailability by way of bypassing the liver metabolism and more efficient dose control for a better patient experience and optimized therapeutic outcomes.
Patents
Cybin has multiple patent filings covering a wide range of novel compounds from different psychedelic classes, including claims to targeted structural modifications to improve the drug pharmacokinetic characteristics and safety profiles without altering their receptor binding.
Cybin’s novel drug delivery platform claims are expected to enable administration of the psychedelic drugs with faster onset of effect, improved bioavailability by way of bypassing the liver metabolism and more efficient dose control for a better patient experience and optimized therapeutic outcomes.
